Kala Bio, INC 8-K filings

Kala Bio, Inc. is implementing a 1-for-50 reverse stock split to adjust its common stock, effective May 8, 2026, with trading on a split-adjusted basis beginning May 11, 2026.

KALA BIO, Inc. announced a strategic shift to become an AI infrastructure partner for the biotechnology industry, securing an exclusive license for Younet AI's Researgency platform.

KALA BIO, Inc. announced the immediate resignation of David Lazar as CEO and CFO, appointing current director Avi Minkowitz to both roles.

KALA BIO, Inc. completed the second closing of its private placement, raising $4.2 million, alongside significant board changes and an increase in authorized common stock.

KALA BIO, Inc. received a notice from Nasdaq regarding non-compliance with the minimum $1.00 bid price requirement, initiating a 180-day compliance period.

KALA BIO, Inc. has entered into an At The Market Offering Agreement with H.C. Wainwright & Co., LLC to sell up to $15 million of common stock.

KALA BIO announced the settlement of approximately $10.6 million in debt with Oxford Finance and resolved other claims by issuing 4.6 million common shares.

KALA BIO, Inc. announced the full satisfaction of its $10.6 million debt obligations to Oxford Finance, LLC through a $2 million payment.

KALA BIO, Inc. announced a change in its independent auditor and conditional resignations of six directors pending shareholder approval of key proposals.

KALA BIO, Inc. announced the dismissal of Deloitte & Touche LLP as its independent registered public accounting firm, effective December 15, 2025.

KALA BIO announced a rescheduled annual meeting, detailed a $1.8 million preferred stock sale to David Lazar, his appointment as CEO and Board Chair, and subsequent transfer of future investment rights.

KALA BIO, Inc. has successfully closed a registered direct offering, raising $10 million in gross proceeds through the sale of common stock and pre-funded warrants.

KALA BIO, Inc. announced a $6.0 million private placement, a debt settlement with Oxford Finance, and significant management changes, including the appointment of David Lazar as CEO, amidst severe financial distress.

KALA BIO, Inc. received a deficiency letter from Nasdaq for failing to meet the minimum market value of listed securities requirement, initiating a 180-day compliance period.

KALA BIO, Inc. has secured a convertible loan of up to $375,000 from an individual investor to fund immediate operational needs and seek further investment, while facing ongoing foreclosure threats from Oxford Finance LLC.

KALA BIO, Inc. announced its secured lender, Oxford Finance LLC, has initiated foreclosure on all assets, swept cash, terminated most employees, and expects delisting from Nasdaq.

KALA BIO amends its prior 8-K to detail $0.4 million in workforce reduction costs and executive retention payments totaling $465,000.

KALA BIO, Inc. received a notice of default from Oxford Finance LLC, accelerating its $29.1 million loan obligation.

KALA BIO announced its lead drug candidate, KPI-012, failed its Phase 2b clinical trial, leading to the cessation of its development and a 51% workforce reduction.

KALA BIO, Inc. announced the date for its 2025 annual meeting of stockholders as December 11, 2025, and established new deadlines for shareholder proposals and director nominations due to the change in meeting date.

KALA BIO, Inc. announced the appointment of Todd Bazemore as its Chief Executive Officer and a Class II director, effective August 29, 2025, alongside a significant increase in his compensation package.

KALA BIO, a clinical-stage biopharmaceutical company, announced completion of patient enrollment in its pivotal Phase 2b CHASE trial for KPI-012 in PCED, with topline data expected by end of September 2025, despite increased Q2 2025 net loss of $11.2 million and cash runway into Q1 2026.

KALA BIO, Inc. announced the successful completion of patient enrollment for its CHASE Phase 2b clinical trial evaluating KPI-012 for the treatment of persistent corneal epithelial defect (PCED), with topline data expected in Q3 2025.

KALA BIO announced its Q1 2025 financial results, highlighting ongoing patient enrollment in the Phase 2b CHASE trial of KPI-012 and a cash runway into Q1 2026.

KALA BIO, Inc. has entered into retention agreements with key executives, including the Interim CEO, CFO, and Head of R&D, to ensure their commitment through the upcoming CHASE clinical trial results.

KALA BIO reports financial results for Q4 and full year 2024, highlights progress on KPI-012 clinical trial, and announces $10.75 million in private placement financing.

Mark Iwicki resigns as CEO of KALA BIO, with Todd Bazemore appointed as interim CEO, effective immediately.

KALA BIO has successfully raised approximately $10.75 million through a private placement to fund the clinical development of KPI-012 and for general corporate purposes.

KALA BIO reported its third quarter 2024 financial results, highlighting progress in its Phase 2b CHASE trial for KPI-012 and providing a corporate update.

Mark S. Blumenkranz, M.D., has resigned from KALA BIO's Board of Directors and associated committees, effective immediately, with no indication of disagreement with the company's operations.